MorieAGertzMDMACP

Hematology • Rochester, MN

Hematologic Oncology

Professor of Hematology & Oncology, Mayo Medical School

Join to view full profile

Dr. Gertz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gertz's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1979 - 1983
Rush University Medical CenterResidency, Internal Medicine, 1976 - 1979
Ascension Illinois/Saint Joseph (Chicago)Residency, Internal Medicine, 1976 - 1976
Loyola University Chicago Stritch School of MedicineClass of 1975
Northwestern UniversityB.A., Arts and Sciences, With Highest Distinction, 1972
Northwestern UniversityBA, Arts and Sciences, with Highest Distinction, 1972

Certifications & Licensure

AZ State Medical License 1989 - 2026
MN State Medical License 1979 - 2025
IL State Medical License 1977 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Jan Waldenstrom Medal for Medical and Scientific Achievements in Waldenstrom's Macroglobulinemia in Parliament Mayo Clinic, 2014
America's Top Doctors Castle Connolly, 2004-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Roland Seidler Jr. Professor of Medicine Mayo Clinic, 2010
Master American College Physicians American College of Physicians, 2010
Bernard L. Schwartz Lecture Scripps Cancer Center, 2010
Excellence in Leadership Award Mayo Clinic, 2008
Robert A. Kyle Award IV International Workshop for Waldenstrom's Macroglobulinemia, 2007
President of Staff Mayo Clinic, 2005
B. J. Kennedy Lectureship Award Minnesota Society of Oncology, 2004
Physician Service Award for Patient Education International Waldenstrom's Macroglobulinemia Foundation (IWMF), 2004
IWMF Physician Service Award for Patient Education International Waldenstrom's Macroglobulinemia Foundation, 2004
President-Elect Officers and Councilors Mayo Clinic, 2003
Distinguished Clinician Award Mayo Clinic, 2002
Flick Family Fund Award Internal Medicine 1979
Physician's Recognition Award in Continuing Medical Education American Medical Association, 1978
Physician's Recognition Award in Continuing Medical Education American Medical Education, 1978
Oliver G. Marcy Scholarship for Academic Achievement 1978
Resident of the Year Internal Medicine Presbyterian - St. Luke's Medical Center, 1978-1979
Alpha omega alpha honors medical society 1975
Alpha Omega Alpha Honors Medical Society Loyola University & Stritch School of Medicine, 1975
Phi Beta Kappa Award Phi Beta Kappa Honor Society, 1972
Join now to see all

Clinical Trials

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse Start of enrollment: 1993 Jun 01
Completed
Phase 2
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 1998 Nov 16
Completed
Phase 2
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 1999 Apr 01
Completed
Phase 2
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia Start of enrollment: 2000 Apr 01
Completed
Phase 2
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation Start of enrollment: 2004 Jan 22
Terminated
Phase 1
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Start of enrollment: 2003 May 01
Completed
Phase 1, Phase 2
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 2005 Oct 01
Completed
Phase 3
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy Start of enrollment: 2013 Mar 15
Completed
Phase 2, Phase 3
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2020 Nov 30
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes.
Charalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, Moritz Binder, Francis K Buadi
Blood Advances. 2025-04-08
Cumulative deficits frailty index and relationship status predict survival in multiple myeloma.
Nadine Abdallah, Paul Dizona, Amanika Kumar, Betsy LaPlant, Terri Menser
Blood Advances. 2025-03-11
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia.
Jonas Paludo, Jithma P Abeykoon, Nirosha D Perera, Shayna Sarosiek, Joshua Gustine
American Journal of Hematology. 2025-03-10

Journal Articles

Systemic Amyloidosis Recognition, Prognosis, and Therapy
Morie A Gertz, Angela Dispenzieri, JAMA
Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma
S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation
Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse
Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis
Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio
Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
Comparable Outcomes Using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Prashant Kapoor, Suzanne R Hayman, Robert C Wolf, William J Hogan, Wilson I Gonsalves, Angela A Dispenzieri, David Dingli,..., Nature
Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...
John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
William J Litchy, Peter D Gorevic, Morie A Gertz, Amil M Shah, John L Berk, Peter J Dyck, The New England Journal of Medicine
Potential new risks of lenalidomide
Gertz MA , Buadi FK, Leuk Lymphoma, 9/1/2014
Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcia-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, ..., Blood, 8/28/2014
Risk adapted therapy for multiple myeloma: back to basics
Kumar SK, Gertz MA, Leuk Lymphoma, 4/22/2014
Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma
Kourelis TV, Kumar SK, Srivastava G, Gertz MA , Lacy MQ, Buadi FK, Kyle RA, Dispenzieri A, Leukemia, 2/1/2014
Immunoglobulin light chain amyloidosis
Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA, Expert Rev Hematol, 2/1/2014
Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients
Thyagarajan B, Arora M, Guan W, Barcelo H, Jackson S, Kumar S, Gertz M, Leuk Res, 11/1/2013
Waldenstrom macroglobulinaemia: the key questions
D'Souza A, Ansell S, Reeder C, Gertz MA, Br J Haematol, 8/1/2013
Second auto-SCT for treatment of relapsed multiple myeloma
Gonsalves WI, Gertz MA , Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Hogan WJ, Kumar SK, Bone Marrow Transplant, 4/1/2013
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia
Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Gertz MA , Novak AJ, Ansell SM, Blood, 11/1/2012
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, Buadi FK, Lacy MQ, Singh PP, Kapoor P, Gertz MA , Kumar SK, Br J Haematol, 8/12/2012
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies
Sinha S, Gertz MA , Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Micallef IN, Hogan WJ, Gastineau DA, Rajkumar SV, Kumar SK, Leukemia, 5/1/2012
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy
Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K, Dispenzieri A, Gertz M , Dingli D, Rajkumar SV, Kumar SK, Leukemia, 4/1/2012
Immunoglobulin light-chain amyloidosis: Growing recognition, new approaches to therapy, active clinical trials
Gertz MA, Dispenzieri A, Oncology, 1/1/2012
Immunoglobulin light chain amyloidosis: 2012 update on diagnosis, prognosis, and treatment
Gertz MA, Am J Hematol, 1/1/2012
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma
Kapoor P, Kumar S, Mandrekar SJ, Laumann KM, Dispenzieri A, Lacy MQ, Dingli D, Gertz MA , Kyle RA, Greipp PR, Rajkumar SV, Witzig TE, Leukemia, 7/1/2011
Join now to see all

Books/Book Chapters

Multiple myeloma: diagnosis and treatment
Gertz MA , Rajkumar SVSpringer, New York2014
Amyloidosis: diagnosis and treatment
Gertz MA , Rajkumar SVHumana Press, New York2010
Hematologic malignancies: multiple myeloma and related plasma cell disorders
Gertz MA , Greipp PRSpringer, Berlin2004
Amyloid and amyloidosis 1998
Kyle RA, Gertz MAEditors: Kyle RA, Gertz MA.The Parthenon Publishing Group, New York1999
Join now to see all

Abstracts/Posters

Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
Morie A Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Morie A. Gertz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
De novo multiple myeloma after kidney transplantation
Safadi S, Leung N, Cosio F, Amer H, Gertz M , Rajkumar V, Hayman S, Lacy M, Dispenzieri A, Am J Kidney Dis, 5/1/2014
Prediction of poor mobilization of autologous cd34+cells in multiple myeloma (mm): implications for risk-stratification
Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Kang Y, Gertz MA , Stuart RK, Kumar SK, Transfusion, 9/1/2013
Electrocardiographic findings in transthyretin-related cardiac amyloidosis
O'Donnell E, Klarich K, Olson A, Lin G, Brady P, Dispenzieri A, Gertz M , Zeldenrust S, Grogan M, J Am Coll Cardiol, 3/1/2013
The natural history of cold agglutinin disease
Swiecicki PL, Hegerova L, Gertz MA, Blood, 11/1/2012
Treatment of advanced heart failure in cardiac amyloidosis with left ventricular assist device therapy
Swiecicki PL, Edwards B, Kushwaha S, Dispenzieri A, Park S, Gertz MA, J Heart Lung Transplant, 4/1/2012
Relapse of poems following autologous stem cell transplantation: a single center experience
D'Souza A, Buadi FK, Lacy MQ, Gertz MA , Hayman SR, Kumar S, Dingli D, Zeldenrust SR, Dispenzieri A, Blood, 11/1/2011
Long term outcome of renal failure in multiple myeloma following autologous stem cell transplant
Glavey SV, Gertz MA , Dispenzieri A, Kumar S, Buadi F, Lacy M, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Leung N, Am J Kidney Dis, 4/1/2011
Join now to see all

Lectures

Adult Clinical Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Training Program DirectorsÍ Workshop
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Training Program DirectorsÍ Workshop
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Trainee Didactic Sessions: How to Set Up a Clinical Research Program
60th American Society of Hematology Annual Meeting - 12/3/2018
Trainee Didactic Sessions: Bridging the Gap: How to Find Clinicians (PhD Topic)
60th American Society of Hematology Annual Meeting - 12/3/2018
Trainee Didactic Sessions: Mentoring and Being Mentored
60th American Society of Hematology Annual Meeting - 12/2/2018
Trainee Didactic Sessions: Basic Statistics for Hematologists
60th American Society of Hematology Annual Meeting - 12/2/2018
Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Survivorship with Active Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Transplant for IgM amyloidosis
London, England - 8/1/2014
Therapy is not indicated for high risk smoldering Waldenstrom Macroglobulinemia Debate
London, England - 8/1/2014
Complications of IgM proteins
London, England - 8/1/2014
Management Strategies for relapsed myeloma
Chicago, IL - 6/1/2014
Amyloidosis
New York City, NY - 5/1/2014
Mayo Clinic Young Investigators Forum
Chicago, IL - 4/1/2014
Interesting patients of monoclonal gammopathy disorders
Herzlia, Israel - 4/1/2014
Monoclonal Gammopathies in the Kidney
Herzlia, Israel - 4/1/2014
Initial therapy for patients with myeloma based on Mayo Clinic criteria
Fukuoka, Japan - 4/1/2014
Initial Therapy for multiple myeloma
Tokyo, Japan - 4/1/2014
Measuring minimal residual disease in multiple myeloma
Abu Dhabi, United Arab Emirates - 3/1/2014
Amyloidosis: Diagnosis & Treatment
Los Angeles, CA - 2/1/2014
Therapy of Amyloidosis
Dallas, TX - 11/1/2013
Join now to see all

Authored Content

Does Stem Cell Transplantation Provide Enough Benefit for Newly Diagnosed Multiple Myeloma Patients?June 2022
Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020
Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020

Press Mentions

Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 MeetingNovember 3rd, 2022
Mayo Clinic Research in the News — 4/26/2021April 26th, 2021
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-cs3) in Hereditary Transthyretin-Mediated Amyloid PolyneuropathyFebruary 26th, 2021
Join now to see all